Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00464347 · ClinicalTrials.gov registry record · Phase 2
TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration
A Phase 2 study, sponsored by National Eye Institute (NEI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00464347 is a Phase 2 study that was terminated before completion, run by National Eye Institute (NEI). The registered enrollment target is 100 participants.
The verdict
NCT00464347, a Phase 2 study, was terminated before completion, sponsored by National Eye Institute (NEI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
VERTACL will investigate whether a triple therapy, Avastin®, half fluence verteporfin photodynamic therapy (PDT), and triamcinolone acetonide-preservative free (TAC- PF), results in improved 12-month vision outcome compared to Avastin® alone in participants with neovascular AMD.
Interventions
- DRUG Avastin
- PROCEDURE Photodynamic Therapy (PDT)
- DRUG Preservative-Free Triamcinolone Acetonide (TAC-PF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-01 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00464347
The ClinicalTrials.gov registry entry for NCT00464347 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Avastin is the first listed.
NCT00464347 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00464347 about?
NCT00464347 is a clinical study titled "TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration". VERTACL will investigate whether a triple therapy, Avastin®, half fluence verteporfin photodynamic therapy (PDT), and triamcinolone acetonide-preservative free (TAC- PF), results in improved 12-month vision outcome compared to Avastin® alone in participants with neovascular AMD.
What is the current status of trial NCT00464347?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2007-01. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00464347?
The interventions under investigation include: Avastin (DRUG), Photodynamic Therapy (PDT) (PROCEDURE), Preservative-Free Triamcinolone Acetonide (TAC-PF) (DRUG).
Who is sponsoring clinical trial NCT00464347?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.